NexImmune, Inc. (NEXI)

NexImmune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	3.22	34.7	30.39	5.1	9.2
Short-Term Investments	0	0	51.49	0	1.01
Cash & Cash Equivalents	3.22	34.7	81.89	5.1	10.2
Cash Growth	-90.71%	-57.63%	1506.05%	-50.03%	-15.40%
Other Current Assets	2.18	2.67	4.39	3.29	0.83
Total Current Assets	5.4	37.37	86.28	8.39	11.04
Property, Plant & Equipment	1.4	5.43	4.43	2.89	2.58
Long-Term Investments	0	0	0	0	0.08
Other Long-Term Assets	1.79	0.26	0.32	0.02	0.02
Total Long-Term Assets	3.19	5.69	4.75	2.91	2.68
Total Assets	8.59	43.06	91.03	11.3	13.72
Accounts Payable	1.34	2.38	1.05	2.76	1.17
Current Debt	0.07	0.6	0	19.12	0
Other Current Liabilities	3.68	7.36	6.17	5.15	1.85
Total Current Liabilities	5.08	10.33	7.22	27.03	3.03
Long-Term Debt	0	0.43	0	0	0
Other Long-Term Liabilities	0	0	0.06	0.03	0.08
Total Long-Term Liabilities	0	0.43	0.06	0.03	0.08
Total Liabilities	5.08	10.76	7.27	27.06	3.11
Total Debt	0.07	1.02	0	19.12	0
Debt Growth	-93.29%	-	-	-	-
Retained Earnings	-222.59	-190.25	-127.74	-77.58	-47.72
Comprehensive Income	0	0	0	0	0
Shareholders' Equity	3.51	32.3	83.76	-69.37	-43.01
Net Cash / Debt	3.15	33.67	81.89	-14.02	10.2
Net Cash / Debt Growth	-90.63%	-58.88%	-	-	-15.40%
Net Cash Per Share	3.00	34.99	101.41	-279.30	205.63
Working Capital	0.32	27.04	79.06	-18.63	8.01
Book Value Per Share	3.34	33.56	103.73	-1382.16	-866.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).